- Omeros (NASDAQ:OMER) jumps 9% in premarket action.
- The FDA has granted an Orphan designation for OMS721 (the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2) for the prevention of TMAs.
- Phase 2 study set to begin in Q1 2014. (PR)
Omeros rises on Orphan designation for OMS721
Recommended For You
More Trending News
About OMER Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| OMER | - | - |
| Omeros Corporation | ||